查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654402

格林-巴利綜合症市場規模、佔有率、趨勢分析報告：按治療方法、類型、給藥途徑、分銷管道、地區、細分預測，2025-2030 年

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

格林-巴利症候群市場成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球格林巴利症候群市場規模預計到 2030 年將達到 10.3 億美元，預測期內的複合年成長率為 6.10%。

格林-巴利綜合症是一種罕見但嚴重的自體免疫疾病，會影響周邊神經系統，其發病率不斷上升，為醫療保健領域帶來了成長機會。公司可以透過治療、診斷工具和患者照護解決方案的進步來利用這一市場擴張。人們對靜脈注射免疫球蛋白 (IVIG) 和血漿置換等有效治療方法的需求日益增加，並且需要透過醫院和零售藥局改善獲得這些治療方法的機會。

GBS 有多種亞型，每種亞型都需要專門的醫療方法。急性發炎性去髓鞘化多發性神經病變 (AIDP) 是北美和歐洲最常見的形式，其特徵是進行性肌肉無力和感覺喪失。慢性脫髓鞘多發性神經炎(CIDP) 雖然是一種相關疾病，但它是一種慢性疾病，需要長期管理策略，因此對治療性介入的需求持續存在。米勒費雪症候群 (MFS) 是一種較為罕見的疾病，主要影響眼球運動和協調能力，需要有針對性的神經系統治療。急性運動軸突神經病變(AMAN) 在亞洲和拉丁美洲更為常見，凸顯了針對特定地區的診斷和治療發展的必要性。

最近爆​​發的格林巴利症候群（GBS）可能與茲卡和其他新興病原體等病毒感染有關，引起了市場越來越多的興趣。病例數量的快速增加促使需要加強監測、早期診斷和及時治療性介入，並鼓勵對醫療基礎設施的投資。政府和製藥公司正在加緊研發，開發新的治療方法並改善現有的通訊協定。新冠肺炎疫情導致靜脈注射免疫球蛋白和血漿置換（治療格林-巴利綜合症的主要治療方法）需求旺盛，這給全球血漿供應鏈帶來了壓力，並促使替代療法的創新。

COVID-19 大流行進一步影響了 GBS 市場，因為研究表明 SARS-CoV-2 感染與 GBS 風險增加之間存在關聯。 COVID-19 病例激增導致報告的格林-巴利綜合症診斷數量增加，並促使對 IVIG 和血漿置換治療的需求增加。此外，疫情導致的醫療供應鏈中斷影響了人們獲得基本治療的機會，並迫使人們在藥品生產和分銷方面做出策略性調整。對病毒感染後神經系統併發症的認知和研究不斷提高，也推動了對格林-巴利症候群診斷和治療創新的投資。

治療方法正在不斷發展，目前正在探索非腸道和口服治療方法。儘管 IVIG 仍然是急性治療的主要方法，但口服免疫調節療法的研究日益增多，這可能為 CIDP 患者提供更容易獲得的長期治療方法。藥房在格林-巴利綜合症治療藥物的分發中發揮關鍵作用。醫院藥房佔據市場主導地位，因為 IVIG 或血漿置換療法期間需要住院護理和密切監測。然而，零售藥局正在擴大其在 CIDP 管理中的作用，為患者提供方便的維持和支持藥物。

由於人們認知的提高、治療方法的不斷發展以及藥品投資的增加，GBS 市場預計將大幅成長。急性和慢性護理解決方案的創新將繼續塑造格局，為醫療保健和治療業務創造新的機會。

格林-巴利症候群市場報告重點

  • 2024 年格林巴利症候群治療市場以靜脈注射免疫球蛋白 (IVIG) 為主。這一優勢源於 IVIG 已被證明具有調節免疫反應、減緩疾病進展和提高康復率的能力，使其成為 GBS 的首選一線治療方法。
  • 2024 年，急性發炎性去髓鞘化多發性神經病變 (AIDP) 在 GBS 亞型中佔據最大的市場佔有率。作為格林巴利症候群最常見的形式，尤其是在北美和歐洲，AIDP疫情正在嚴重影響對有效治療方案的需求，進一步加強了市場主導地位。
  • 2024 年，腸外藥物將引領 GBS 治療市場。鑑於疾病的嚴重性，靜脈注射免疫球蛋白（IVIG）和血漿置換等靜脈注射治療可確保快速有效的治療反應，改善急性和重症患者的預後。
  • 2024年，醫院藥局仍將是主要的分銷管道。由於需要即時進行醫療干預和專門護理，醫院藥房在確保格林-巴利綜合症治療的可用性和管理方面發揮關鍵作用，尤其是在急性護理環境中。
  • 由於醫療保健基礎設施發達、對神經系統疾病的高度認知以及先進的治療選擇，北美在 GBS 治療市場處於領先地位。該地區對研究和創新的高度重視進一步推動了市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 格林-巴利症候群市場變數、趨勢與範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 格林-巴利症候群分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章 格林-巴利綜合症市場：治療方法估計和趨勢分析

  • 格林-巴利綜合症市場：治療方法細分儀表板
  • 格林-巴利綜合症市場：2024 年和 2030 年治療方法變異分析
  • 靜脈注射免疫球蛋白（IVIG）
  • 血漿置換
  • 其他

第 5 章 格林-巴利綜合症市場：按類型估計和趨勢分析

  • 格林-巴利綜合症市場：類型細分儀表板
  • 格林-巴利症候群市場：類型變異分析，2024 年與 2030 年
  • 急性發炎性去髓鞘化多發性神經病變 (AIDP)
  • 慢性發炎性去髓鞘化多發性神經根神經病變 (CIDP)
  • 米勒費雪症候群（MFS）
  • 急性運動軸索神經病變 (AMAN)
  • 其他

第 6 章 格林-巴利綜合症市場：按給藥途徑進行的估計和趨勢分析

  • 格林-巴利症候群市場：給藥途徑細分儀表板
  • 格林-巴利綜合症市場：2024 年和 2030 年按給藥途徑進行的變化分析
  • 腸外
  • 口服

第 7 章 格林-巴利綜合症市場：按分銷管道進行的估計和趨勢分析

  • 格林-巴利綜合症市場：分銷通路細分儀表板
  • 格林-巴利綜合症市場：2024 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥局
  • 其他藥局

第 8 章 格林-巴利綜合症市場：按地區分類的估計和趨勢分析

  • 格林-巴利綜合症市場佔有率（按地區分類），2024 年和 2030 年，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 南非

第9章 競爭格局

  • 主要市場參與企業的近期趨勢及影響分析
  • 公司分類
  • 2024 年公司市場佔有率分析
  • 2024 年企業熱圖分析
  • 公司簡介
    • AbbVie Inc.
    • Biogen
    • Cadila Pharmaceuticals
    • CSL
    • F. Hoffmann-La Roche Ltd.
    • GSK plc.
    • Grifols SA
    • LGM Pharma.
    • Merck &Co., Inc.
    • Octapharma AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-200-8

Guillain-Barre Syndrome Market Growth & Trends:

The global guillain-Barre syndrome market size is anticipated to reach USD 1.03 billion by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barre Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights:

  • Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barre Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG's proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.
  • Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.
  • Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.
  • North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of Guillain-Barre Syndrome (GBS)
      • 3.3.1.2. Government regulations and guidelines
      • 3.3.1.3. Advancements in treatment options
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Side effects and adverse reactions
      • 3.3.2.2. High cost treatment
  • 3.4. Guillain-Barre Syndrome Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

  • 4.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
  • 4.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Intravenous Immunoglobulin (IVIG)
    • 4.3.1. Intravenous Immunoglobulin (IVIG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Plasma Exchange
    • 4.4.1. Plasma Exchange Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

  • 5.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
  • 5.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
    • 5.3.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    • 5.4.1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Miller Fisher Syndrome (MFS)
    • 5.5.1. Miller Fisher Syndrome (MFS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Acute Motor Axonal Neuropathy (AMAN)
    • 5.6.1. Acute Motor Axonal Neuropathy (AMAN) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other
    • 5.7.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Guillain-Barre Syndrome Market: Route of Administration Segment Dashboard
  • 6.2. Guillain-Barre Syndrome Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Parenteral
    • 6.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Guillain-Barre Syndrome Market: Distribution Channel Segment Dashboard
  • 7.2. Guillain-Barre Syndrome Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Pharmacies
    • 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

  • 8.1. Guillain-Barre Syndrome Market Share, By Region, 2024 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Norway
      • 8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Kuwait
      • 8.6.4.1. Kuwait Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Africa
      • 8.6.5.1. South Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis, 2024
  • 9.5. Company Profiles
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Participant's Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Recent Developments/ Strategic Initiatives
    • 9.5.2. Biogen
      • 9.5.2.1. Participant's Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Recent Developments/ Strategic Initiatives
    • 9.5.3. Cadila Pharmaceuticals
      • 9.5.3.1. Participant's Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Recent Developments/ Strategic Initiatives
    • 9.5.4. CSL
      • 9.5.4.1. Participant's Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Recent Developments/ Strategic Initiatives
    • 9.5.5. F. Hoffmann-La Roche Ltd.
      • 9.5.5.1. Participant's Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Recent Developments/ Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Participant's Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Recent Developments/ Strategic Initiatives
    • 9.5.7. Grifols S.A.
      • 9.5.7.1. Participant's Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Recent Developments/ Strategic Initiatives
    • 9.5.8. LGM Pharma.
      • 9.5.8.1. Participant's Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Recent Developments/ Strategic Initiatives
    • 9.5.9. Merck & Co., Inc.
      • 9.5.9.1. Participant's Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Recent Developments/ Strategic Initiatives
    • 9.5.10. Octapharma AG
      • 9.5.10.1. Participant's Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Recent Developments/ Strategic Initiatives
    • 9.5.11. Pfizer Inc.
      • 9.5.11.1. Participant's Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Recent Developments/ Strategic Initiatives
    • 9.5.12. Takeda Pharmaceutical Company Limited
      • 9.5.12.1. Participant's Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 5 Global Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 9 North America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 13 U.S. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 17 Canada Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 21 Mexico Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 25 Europe Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Europe Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 29 Germany Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Germany Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 U.K. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 U.K. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 33 U.K. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 U.K. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 France Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 France Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 37 France Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 France Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Italy Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 Italy Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 41 Italy Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Italy Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Spain Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Spain Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 45 Spain Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Spain Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Denmark Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Denmark Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 49 Denmark Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Denmark Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Sweden Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Sweden Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 53 Sweden Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Sweden Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Norway Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 56 Norway Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 57 Norway Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Norway Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 China Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 China Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 65 China Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 China Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Japan Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 69 Japan Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Japan Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 India Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 India Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 73 India Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 India Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 South Korea Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 77 South Korea Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 South Korea Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 81 Australia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Australia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Thailand Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 85 Thailand Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Thailand Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Latin America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 89 Latin America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 93 Brazil Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Argentina Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 97 Argentina Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 Argentina Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 South Africa Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 105 South Africa Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 111 UAE Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 112 UAE Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 113 UAE Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 114 UAE Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Guillain-Barre syndrome market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook, 2024 (USD billion)
  • Fig. 11 Market trends & outlook
  • Fig. 12 Porter's five force analysis
  • Fig. 13 PESTEL analysis
  • Fig. 14 Guillain-Barre Syndrome market: Therapeutics outlook and key takeaways
  • Fig. 15 Guillain-Barre Syndrome market: Therapeutics movement analysis
  • Fig. 16 Intravenous Immunoglobulin (IVIG) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Plasma Exchange market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Guillain-Barre Syndrome market: Type outlook and key takeaways
  • Fig. 20 Guillain-Barre Syndrome market: Type movement analysis
  • Fig. 21 Acute Inflammatory Demyelinating Polyneuropathy (AIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Miller Fisher Syndrome (MFS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Acute Motor Axonal Neuropathy (AMAN) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Guillain-Barre Syndrome market: Route of administration outlook and key takeaways
  • Fig. 27 Guillain-Barre Syndrome market: Route of administration movement analysis
  • Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Parenteral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Guillain-Barre Syndrome market: Distribution channel outlook and key takeaways
  • Fig. 31 Guillain-Barre Syndrome market: Distribution channel movement analysis
  • Fig. 32 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Other pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 Regional Outlook, 2024 & 2030
  • Fig. 37 Global Guillain-Barre syndrome market, Region Movement Analysis
  • Fig. 38 North America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 44 U.K. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 45 France Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 53 China Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 54 India Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 64 UAE Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait Guillain-Barre syndrome market, 2018 - 2030 (USD Million)